Antibodies to watch in 2020
暂无分享,去创建一个
[1] Econor,et al. ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS , 2002 .
[2] M. Odell,et al. The hormone-releasing intrauterine device has benefits over hysterectomy for many women. Press release. , 2009, Acta obstetricia et gynecologica Scandinavica.
[3] J. Reichert. Antibodies to watch in 2010 , 2010, mAbs.
[4] J. Reichert. Antibody-based therapeutics to watch in 2011 , 2011, mAbs.
[5] P. Moore,et al. Anti-tumor activity and toxicokinetics analysis of MGAH22, an anti-HER2 monoclonal antibody with enhanced Fcγ receptor binding properties , 2011, Breast Cancer Research.
[6] J. Reichert. Which are the antibodies to watch in 2012? , 2012, mAbs.
[7] J. Reichert. Antibodies to watch in 2013 , 2013, mAbs.
[8] M. Schrappe,et al. The Fc-engineered CD19 antibody MOR208 (XmAb5574) induces natural killer cell-mediated lysis of acute lymphoblastic leukemia cells from pediatric and adult patients , 2013, Leukemia.
[9] Janice M. Reichert,et al. Which are the antibodies to watch in 2013? , 2013, mAbs.
[10] Janice M Reichert,et al. Antibodies to watch in 2014 , 2014, mAbs.
[11] M. Blanusa,et al. Retrocyte Display® technology: generation and screening of a high diversity cellular antibody library. , 2014, Methods.
[12] Janice M Reichert,et al. Antibodies to watch in 2014 , 2014, mAbs.
[13] Janice M Reichert,et al. Antibodies to watch in 2015 , 2015, mAbs.
[14] J. Reichert. Antibodies to watch in 2016 , 2016, mAbs.
[15] R. Maciuca,et al. OP011 Etrolizumab treatment leads to early improvement in symptoms and inflammatory biomarkers in anti-TNF-refractory patients in the open-label induction cohort of the phase 3 HICKORY study. , 2017, Journal of Crohn's & colitis.
[16] Janice M. Reichert,et al. Antibodies to watch in 2017 , 2016, mAbs.
[17] Form 8-K,et al. UNITED STATES SECURITIES AND EXCHANGE COMMISSION , 2017 .
[18] R. Maciuca,et al. Etrolizumab Treatment Leads to Early Improvement in Symptoms and Inflammatory Biomarkers in Anti-TNF-refractory Patients in the Open-Label Induction Cohort of the Phase 3 Hickory Study , 2017 .
[19] Terry J. Smith,et al. Teprotumumab for Thyroid‐Associated Ophthalmopathy , 2017, The New England journal of medicine.
[20] P. Weinreb,et al. Structural and kinetic basis for the selectivity of aducanumab for aggregated forms of amyloid-β , 2018, Scientific Reports.
[21] E. H. Thompson,et al. Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials , 2018, The Lancet.
[22] J. Reichert,et al. Antibodies to watch in 2018 , 2018, mAbs.
[23] Y. Sakurai,et al. Development of Clinical-Stage Human Monoclonal Antibodies That Treat Advanced Ebola Virus Disease in Nonhuman Primates , 2018, The Journal of infectious diseases.
[24] M. Neurath,et al. Cellular Mechanisms of Etrolizumab Treatment in Inflammatory Bowel Disease , 2019, Front. Pharmacol..
[25] FDA approves first targeted therapy to treat patients with painful complication of sickle cell disease , 2019, Case Medical Research.
[26] Galaxy Surfactants: financial results for the quarter and nine months ended 31 Dec 2018 , 2019, Focus on Surfactants.
[27] T. Schnitzer,et al. Effect of Tanezumab on Joint Pain, Physical Function, and Patient Global Assessment of Osteoarthritis Among Patients With Osteoarthritis of the Hip or Knee: A Randomized Clinical Trial. , 2019, JAMA.
[28] D. Schadendorf,et al. The anti–PD-1 antibody spartalizumab (S) in combination with dabrafenib (D) and trametinib (T) in previously untreated patients (pts) with advanced BRAF V600–mutant melanoma: Updated efficacy and safety from parts 1 and 2 of COMBI-I. , 2019, Journal of Clinical Oncology.
[29] S. Tishchenko,et al. Fab Fragment of VHH-Based Antibody Netakimab: Crystal Structure and Modeling Interaction with Cytokine IL-17A , 2019, Crystals.
[30] Efficacy and safety of continuous Q12W risankizumab versus treatment withdrawal: Results From the phase 3 IMMhance Trial , 2019, Journal of the American Academy of Dermatology.
[31] FDA approves new treatment for osteoporosis in postmenopausal women at high risk of fracture , 2019, Case Medical Research.
[32] C. Rudin,et al. Efficacy and Safety of Rovalpituzumab Tesirine in Third-Line and Beyond Patients with DLL3-Expressing, Relapsed/Refractory Small-Cell Lung Cancer: Results From the Phase II TRINITY Study , 2019, Clinical Cancer Research.
[33] D. Goldenberg,et al. Antibody-drug conjugates targeting TROP-2 and incorporating SN-38: A case study of anti-TROP-2 sacituzumab govitecan , 2019, mAbs.
[34] Michael Proschan,et al. A Randomized, Controlled Trial of Ebola Virus Disease Therapeutics. , 2019, The New England journal of medicine.
[35] M. Garber,et al. Fab Fragment of VHH-Based Antibody Netakimab: Crystal Structure and Modeling Interaction with Cytokine IL-17A , 2019 .
[36] F. Prósper,et al. The Mechanism of Action of the Anti-CD38 Monoclonal Antibody Isatuximab in Multiple Myeloma , 2019, Clinical Cancer Research.
[37] W. Gradishar,et al. SOPHIA primary analysis: A phase 3 (P3) study of margetuximab (M) + chemotherapy (C) versus trastuzumab (T) + C in patients (pts) with HER2+ metastatic (met) breast cancer (MBC) after prior anti-HER2 therapies (Tx). , 2019, Journal of Clinical Oncology.
[38] M. Shi,et al. Effect of crizanlizumab on pain crises in subgroups of patients with sickle cell disease: A SUSTAIN study analysis , 2018, American journal of hematology.
[39] Jacqueline Palace,et al. Trial of Satralizumab in Neuromyelitis Optica Spectrum Disorder. , 2019, The New England journal of medicine.
[40] E. H. Thompson,et al. Risankizumab compared with adalimumab in patients with moderate-to-severe plaque psoriasis (IMMvent): a randomised, double-blind, active-comparator-controlled phase 3 trial , 2019, The Lancet.
[41] U. Schmidt-Erfurth,et al. HAWK and HARRIER: Phase 3, Multicenter, Randomized, Double-Masked Trials of Brolucizumab for Neovascular Age-Related Macular Degeneration. , 2019, Ophthalmology.
[42] Gary R Cutter,et al. Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2/3 trial , 2019, The Lancet.
[43] Janice M Reichert,et al. Antibodies to watch in 2019 , 2018, mAbs.
[44] M. Galsky,et al. EV-201: Results of enfortumab vedotin monotherapy for locally advanced or metastatic urothelial cancer previously treated with platinum and immune checkpoint inhibitors. , 2019, Journal of Clinical Oncology.
[45] J. Krischer,et al. An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 Diabetes. , 2019, The New England journal of medicine.
[46] Hilary J Allen,et al. The United States Securities and Exchange Commission , 2020 .